CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Merck & CO INC. (MRK) / belzutifan
Forward catalyst · MRK

belzutifan

Sponsor Merck & CO INC. · listed as MRK

READOUT Phase 3 Confidence: medium Source: clinicaltrials

belzutifan is a clinical-stage drug asset sponsored by Merck & CO INC., listed as MRK. CSA tracks 3 forward catalysts for it — the nearest is a readout expected Oct 28, 2026 (day precision, medium confidence), tied to trial NCT05239728. The asset is in Phase 3 and currently active not recruiting, studied in Carcinoma, Renal Cell. It appears across 8 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-10-28
As disclosedOct 28, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05239728
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorMerck Sharp & Dohme LLC
Listed asMRK
Condition(s)Carcinoma, Renal Cell

All tracked catalysts for belzutifan

DateEventConfidenceTrial
2026-10-28READOUTmediumNCT05239728
2026-10-29READOUTmediumNCT04736706
2027-06-07READOUTmediumNCT05899049
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More MRK catalysts